HEALTH OF WOMAN. 2017.10(126):137–146

Rhoda H. Cobin, MD, MACE1; Neil F. Goodman, MD, FACE2;
от имени Научного комитета по репродуктивной эндокринологии AACE
Адаптировано – С.А. Шурпяк
Литература

1. Goodman NF, Cobin RH, Ginzburg SB, et al. AACE medical guidelines for clinical practice for diagnosis and treatment of meno-pause. Endocr Pract. 2011;17(suppl 6).

2. Wharton W, Gleason CE, Mill VM, Asthana S. Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog). Brain Res. 2013;1514:12-17. https://doi.org/10.1016/j.brainres.2013.04.011; PMid:23603409 PMCid:PMC3731133

3. NAMS 23rd Annual Meeting, Orlando, Florida, October 3-6, 2012. Available at: http://www.menopause.org/annual meetings/2012-meeting/keeps-report. Accessed May 25,2017.

4. Hodis HN, Mack WJ, Henderson VW, et al. Vasuclar effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374:1221-1231. https://doi.org/10.1056/NEJMoa1505241; PMid:27028912 PMCid:PMC4921205

5. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. https://doi.org/10.1136/bmj.e6409; PMid:23048011

6. Rossouw JE, Manson JE, Kaunitz AM, Stefanick ML. Study had insufficient power to investigate safety. BMJ. 2012; 345: e8146. https://doi.org/10.1136/bmj.e8146; PMid:23208257

7. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended posts stopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310:1353-1368. https://doi.org/10.1001/jama.2013.278040; PMid:24084921 PMCid:PMC3963523

8. Bassuk SS, Manson JE. Menopausal hormone therapy and cardiovascular disease risk: utility of biomarkers and clinical factors for risk stratification. Clin Chem. 2014;60:68-77. https://doi.org/10.1373/clinchem.2013.202556; PMid:24379312

9. Wild RA, Wu C, Curb JD, et al. Coronary heart disease events in the Women’s Health Initiative hormone trials: effect modification by metabolic syndrome: a nested casecontrol study within the Women’s Health Initiative randomized clinical trials. Menopause. 2013;20:254-260. PMid:23435021 PMCid:PMC4279916

10. Wolff EF, He Y, Black DM, et al. Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos early estrogen prevention study (KEEPS). Fertil Steril. 2013;99:1385-1391. https://doi.org/10.1016/j.fertnstert.2012.11.053; PMid:23312232 PMCid:PMC3615128

11. Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause. 2009;16:639-643. https://doi.org/10.1097/gme.0b013e31819c11e4; PMid:19325499 PMCid:PMC2856618

12. Thurston RC, Chang Y, Barinas-Mitchell E, et al. Menopausal hot flashes and carotid intima media thickness among midlife women. Stroke. 2016; 47: 2910-2915. https://doi.org/10.1161/STROKEAHA.116.014674; PMid:27834746 PMCid:PMC5134903

13. Crandall C, Manson JE, Hohensee C, et al. Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Womens’ Health Initiative Study. Menopause. 2017;24:252-261. https://doi.org/10.1097/GME.0000000000000763; PMid:28231077

14. Poіaж I, Borowiecka M, Wilamowska A, Nowak P. Coagulation and fibrinolytic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration. Gynecol Endocrinol. 2013;29:165-168. https://doi.org/10.3109/09513590.2012.730567; PMid:23116237

15. Slater CC, Zhang C, Hodis HN, et al. Comparison of estrogen and androgen levels after oral estrogen replacement therapy. J Reprod Med. 2001;46:1052-1056. PMid:11789085

16. L’Hermite M. HRT optimization using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric. 2013;16(suppl 1):44-53. https://doi.org/10.3109/13697137.2013.808563; PMid:23848491

17. Canonico M, Plu-Bureau G, Lowe G, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336:1227-1231. https://doi.org/10.1136/bmj.39555.441944.BE; PMid:18495631 PMCid:PMC2405857

18. Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10:2277-2286. https://doi.org/10.1111/j.1538-7836.2012.04919.x; PMid:22963114

19. Shufelt CL, Merz CN, Prentice RL, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women’s Health Initiative Observational Study. Menopause. 2014;21:260-266. https://doi.org/10.1097/GME.0b013e31829a64f9; PMid:24045672 PMCid:PMC3872264

20. Renoux C, Dell’aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519. https://doi.org/10.1136/bmj.c2519; PMid:20525678

21. Qureshi AI, Malik AA, Saeed O, Defillo A, Sherr GT, Suri MF. Hormone replacement therapy and the risk of subarachnoid hemorrhage in postmenopausal women. J Neurosurg. 2016:124:45-50. https://doi.org/10.3171/2014.12.JNS142329; PMid:26162033

22. Fournier A, Fabre A, Mesrine S, et al. Use of different postmenopausal hormone therapies and risk of histologyand hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008;26:1260-1268. https://doi.org/10.1200/JCO.2007.13.4338; PMid:18323549 PMCid:PMC2346534

23. Brinton LA, Smith L, Gierach GL, et al. Breast cancer risk in older women: results from the NIH-AARP diet and health study. Cancer Causes Control. 2014;25:843-857. https://doi.org/10.1007/s10552-014-0385-3; PMid:24810653 PMCid:PMC4426978

24. Bourgain C, Devroey P, Van Waesberghe l, Smitz J, Van Steirteghem A. Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod. 1990;5:537-543. https://doi.org/10.1093/oxfordjournals.humrep.a137138; PMid:2394784

25. Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol. 2010; 172: 1394-1403. https://doi.org/10.1093/aje/kwq300; PMid:20961969

26. Biberoglu EH, Tanrэkulu F, Erdem M, Erdem A, Biberoglu KO. Luteal phase support in intrauterine insemination cycles: a prospective randomized study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecol Endocrinol. 2016;32:55-57. https://doi.org/10.3109/09513590.2015.1077382; PMid:26291817

27. Fernбndez-Murga L, Hermenegildo C, Tarнn JJ, Garcнa-Pйrez MБ, Cano A. Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol. Climacteric. 2012; 15: 455-459. https://doi.org/10.3109/13697137.2011.644360; PMid:22321028

28. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012;8:CD000402. https://doi.org/10.1002/14651858.CD000402.pub4

29. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol. 2010; 30: 340-345. https://doi.org/10.1161/ATVBAHA.109.196022; PMid:19834106

30. Stanczyk FZ, Bhavnani BR. Reprint of “Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?” J Steroid Biochem Mol Biol. 2015;153:151-159. https://doi.org/10.1016/j.jsbmb.2015.08.013; PMid:26291834

31. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol. 2003;21:4314-4321. https://doi.org/10.1200/JCO.2003.05.151; PMid:14645420

32. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update. 2005;11:545-560. Erratum 2006;12:331. https://doi.org/10.1093/humupd/dmi028; PMid:16150813

33. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114:448-454. https://doi.org/10.1002/ijc.20710; PMid:15551359

34. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34:171-208. https://doi.org/10.1210/er.2012-1008; PMid:23238854 PMCid:PMC3610676

35. Shao H, Breitner JC, Whitmer RA, et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology. 2012; 79: 1846-1852. https://doi.org/10.1212/WNL.0b013e318271f823; PMid:23100399 PMCid:PMC3525314

36. Stuenkel CA. Menopause hormone therapy and diabetes. Climacteric. 2017; 20: 11-21. https://doi.org/10.1080/13697137.2016.1267723; PMid:28064520

37. Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clin Proc. 2011;86:673-680. https://doi.org/10.4065/mcp.2010.0714; PMid:21531972 PMCid:PMC3127562

38. Galson SK. Pharmacy Compounding/ Compounding of Bio-identical Hormone Replacement Therapies. Available at: https: //www.fda.gov/newsevents/testimony/ucm154031.htm. Accessed May 31, 2017.

39. Available at: http://www.fda.gov/forconsumers/byaudience/forwomen/ucm118624.htm.

40. Sharifi M, Lewiecki EM. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. Expert Rev Clin Pharmacol. 2014;7:281-291. https://doi.org/10.1586/17512433.2014.893819; PMid:24580081

41. Mirkin S, Komm BS. Tissue-selective estrogen complexes for postmenopausal women. Maturitas. 2013;76:213-220. https://doi.org/10.1016/j.maturitas.2013.06.003; PMid:23849704

42. Rosen HN, Rosen CJ, Mulder JE. Selective estrogen receptor modulators, Up to Date. 2017.

43. Rietjens IM, Louisse J, Beekmann. The potential health effects of dietary phytoestrogens. Br J Pharmacol. 2017; 174: 1263-1280. https://doi.org/10.1111/bph.13622; PMid:27723080 PMCid:PMC5429336

44. Guthrie KA, LaCroix AZ, Ensrud KE, et al. Pooled analysis of six pharmacologic and nonpharmacologic interventions for vasomotor symptoms. Obstet Gynecol. 2015;126:413-422. https://doi.org/10.1097/AOG.0000000000000927; PMid:26241433 PMCid:PMC4526122

45. Carroll DG, Lisenby KM, Carter TL. Critical appraisal of paroxetine for the treatment of vasomotor symptoms. Int J Womens Health. 2015;7:615-624. https://doi.org/10.2147/IJWH.S50804; PMid:26124682 PMCid:PMC4476484

46. Binkhorst L, Mathijssen RH, van Herk-Sukel MP, et al. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat. 2013;139:923-929. https://doi.org/10.1007/s10549-013-2585-z; PMid:23760858

47. Saadati N, Mohammadjafari R, Natanj S, Abedi P. The effect of gabapentin on intensity and duration of hot flashes in postmenopausal women: a randomized controlled trial. Glob J Health Sci. 2013;5:126-130. https://doi.org/10.5539/gjhs.v5n6p126; PMid:24171880 PMCid:PMC4776854

48. Pinkerton JV, Kagan R, Portman D, Sathyanarayana R, Sweeney M. Phase 3 randomized controlled study of gastro-retentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. Menopause. 2014;21:567-573. https://doi.org/10.1097/GME.0b013e3182a7c073; PMid:24149930

49. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010;28:5147-5152. https://doi.org/10.1200/JCO.2010.29.9230; https://doi.org/10.1200/jco.2010.28.15_suppl.9023; PMid:21060031

50. L’Espйrance S, Frenette S, Dionne A, Dionne JY. Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer. 2013;21:1461-1474. https://doi.org/10.1007/s00520-013-1732-8; PMid:23435567

51. Overk CR, Yao P, Chen S, et al. High-content screening and mechanism-based evaluation of estrogenic botanical extracts. Comb Chem High Throughput Screen. 2008;11:283-293. https://doi.org/10.2174/138620708784246022; PMid:18473738 PMCid:PMC3219440

52. Gaube F, Wolfl S, Pusch L, Kroll TC, Hamburger M. Gene expression profiling reveals effects of Cimicifuga racemosa (L.) NUTT. (black cohosh) on the estrogen receptor positive human breast cancer cell line MCF-7. BMC Pharmacol. 2007;7:11. https://doi.org/10.1186/1471-2210-7-11; PMid:17880733 PMCid:PMC2194763

53. Mercado-Feliciano M, Cora MC, Witt KL, et al. An ethanolic extract of black cohosh causes hematological changes but not estrogenic effects in female rodents. Toxicol Appl Pharmacol. 2012;263:138-147. https://doi.org/10.1016/j.taap.2012.05.022; PMid:22687605 PMCid:PMC3422379

54. Bolle P, Mastrangelo S, Perrone F, Evandri MG. Estrogen-like effect of a Cimicifuga racemosa extract subfraction as assessed by in vivo, ex vivo and in vitro assays. J Steroid Biochem Mol Biol. 2007;107:262-269. https://doi.org/10.1016/j.jsbmb.2007.03.044; PMid:17689956

55. Fritz H, Seely D, McGowan J, et al. Black cohosh and breast cancer: a systematic review. Integr Cancer Ther. 2014; 13: 12-29. https://doi.org/10.1177/1534735414534463; https://doi.org/10.1177/1534735413477191; PMid:23439657HEALTH OF WOMAN. 2017.10(126):137–146